Is ABT-494 the Next JAK Inhibitor? Save

Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.

There are 2 reports in the curent issue of Arthritis & Rheumatology on the efficacy and safety of another selective JAK-1 inhibitor, ABT-494, in treating rheumatoid arthritis (RA) especially in those with an inadequate response to methotrexate (MTX) or a TNF inhibitor.  http://buff.ly/2h37nYo   http://buff.ly/2gQJzE8

In one study authored by Genovese et al, 300 patients with MTX-IR RA received 12 weeks of ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo. Overall, ABT-494 had greater responses than placebo (62-80% percent versus 46%) treated patients.

Another trial authored by Kremer et al. looked at 276 RA patieints on a stable dose of MTX, who failed or were intolerant to an anti-TNF agent. ABT-494 outperformed PBO with and an ACR20 response of 53-71%, compared to placebo (34%).

These reports suggest comparative efficacy and safey with existing or other potential JAK inhibitors.